Most Recent Posts
Earlier this week, a joint plan was outlined by the Office of National Drug Control Policy (ONDCP), the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA), where key strategies were developed that address preventing prescription drug abuse nationwide. A full outline of the plan can be found here.
As we've noted in previous blog posts, counterfeit medicines are becoming more prevalent around the world. Many foreign countries have been experiencing an influx of counterfeit drugs because they have a weaker regulatory regime compared to the U.S. and/or open drug supply system. In the U.S., however, our closed drug supply system has helped shield patients from the dangerous worldwide counterfeit medicines epidemic.
I admit that this blog post comes to you a few days late. As I read through coverage of PhRMA's annual meeting, this article in The Newark Star-Ledger caught my eye.
With PhRMA's annual meeting completed, everyone here is getting back into their more normal routines. So, I thought I'd start the week talking about a piece in today's New York Times Health Section.
An interview with The Catalyst and Orexigen CEO Mike Narachi
1. Talk about what it is for a company like Orexigen to become a member of PhRMA?
We're obviously excited because our goals align so closely with those of PhRMA. As a small company with a late-stage product, we understand the importance of creating an environment that fosters innovation, and becoming a member of PhRMA -- a group that has made innovation such a priority -- was a natural fit.
Two Women Scientists Honored with PhRMA's 2011 Discoverers Award
There are a lot of interesting discussions and events during PhRMA's Annual Meeting, but one regular event is always special. That is the annual awarding of PhRMA's Discoverers Award.
This is a guest post from Brian Reid, Director at WCG.
Judging from the agenda, the PhRMA Annual Meeting was about leaders: yesterday's Session started with an introduction by PhRMA chairman and sanofi-aventis CEO Chris Viehbacher, followed by New Jersey Governor Chris Christie, Duke basketball coach Mike Krzyzewski and others. All spoke about the importance of investment and the need to have clear, thoughtful regulation to nurture that innovation.
[11:00 a.m.] At the PhRMA Annual Meeting, we set up a "listening gallery," a wall on which participants were invited to share their thoughts on what innovation truly is.
Here are a few samples.
Below, we sat down with Marc Boutin, executive vice president and COO of the National Health Council, for his thoughts on the PhRMA annual meeting.
1. Tell us a bit more about your background and role at the National Health Council.
In launching this blog earlier this year, we said that our goal would be to create a place to share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you and learn together. Now, as we approach our annual meeting, beginning Thursday, we think it's the perfect time and place to create opportunities for members of our community to be an active part of the conversation.
Below, we sat down with Ellen Sigal, chairperson and founder of Friends of Cancer Research, for her thoughts about the upcoming PhRMA annual meeting.
1. What message are you bringing to the PhRMA annual meeting?
Later this week, PhRMA will be conducting our 2011 Annual Meeting, convening stakeholders from across the spectrums of healthcare, policy and regulation. Here, I speak with sanofi-aventis CEO Chris Viehbacher - who also serves as the chairman of PhRMA's board, about one of his priority issues for the meeting.
Can you tell us more about why prevention is one of the three themes of this year's PhRMA Annual Meeting?